SOURCE: Prima BioMed Ltd

October 12, 2016 21:36 ET

Prima to Present at 2016 Society for Immunotherapy of Cancer Conference

SYDNEY, AUSTRALIA--(Marketwired - Oct 12, 2016) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) ("Prima") announces that the submission titled "LAG-3Ig (IMP321) in combination with anti-PD-1 therapy" has been accepted for a presentation at the Society for Immunotherapy of Cancer (SITC)'s New Cancer Immunotherapy Agents in Development program.

This program, which is part of SITC 2016, is being held on Wednesday, November 9, 2016 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland. Dr Frédéric Triebel, Prima's Chief Medical & Scientific Officer, will deliver the presentation between 11:10am and 12:20pm.

About Prima BioMed

Prima BioMed is listed on the Australian Securities Exchange, and on the NASDAQ in the US. For further information please visit

Contact Information